EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

The Histone Deacetylase Inhibitor Entinostat Mediates HER2 Downregulation in Gastric Cancer, Providing the Basis for Its Particular Efficacy in HER2-Amplified Tumors and in Combination Therapies

Tamara Zenz, Robert Jenke, René Thieme, Tim Kahl, Hannes Borchardt, Ines Gockel, Finn K Hansen, Achim Aigner, Thomas R H Büch

Cancer Research and Treatment · 2025

DOI: 10.4143/crt.2024.546 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Research and Treatment, 2025. Verfasst von Tamara Zenz und 8 weiteren Autor:innen. Beteiligte Einrichtung: Leipzig University, Medical Faculty, Rudolf-Boehm-Institute for Pharmacology and Toxicology, Clinical Pharmacology, Leipzig, Germany. Hauptthemen laut MEDLINE: Stomach Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Histone Deacetylase Inhibitors, Pyridines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Roland-Ernst-Stiftung für Gesundheitsforschung, German Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Human epidermal growth factor receptor 2 (HER2) inhibition represents a therapeutic approach with proven clinical efficacy in gastric cancer. However, resistance against HER2-directed therapeutics highlights the need for alternative approaches or drug combinations. Histone deacetylase inhibitors (HDACi) display a broad spectrum of antitumor properties, which may include effects on receptor tyrosine kinases.Materials and Methods We analyzed the effects of the class I HDACi entinostat in a panel of HER2-amplified and non-amplified gastric adenocarcinoma cells in 2D cell culture as well as in tumor slice models ex vivo and in patient-derived xenografts in vivo. Effects on protein expression/signal transduction were evaluated by immunoblotting and quantitative reverse transcription polymerase chain reaction.

Results

HDAC inhibition reduced HER2 protein expression independently of initial HER2 expression levels. This was associated with the upregulation of the HER2-inhibiting microRNA miR-205. The downregulation of HER2 resulted in reduced AKT phosphorylation, apoptosis induction and antiproliferative effects, with particularly high efficiency in HER2-amplified gastric cancer cells. Inhibiting HER2 by a specific kinase inhibitor in gastric cancer cells with low basal HER2 expression led to HER2 upregulation. This was reversed by entinostat treatment and provided the basis for synergistic cell inhibition upon double treatment.

Conclusion

We describe the downregulation of HER2 in gastric carcinoma cells upon HDACi treatment. Concomitantly, cells with high basal or treatment-induced HER2 expression showed most profound sensitivities towards HDACi. These findings may thus provide the basis for HDACi treatment as a therapeutic option particularly valuable in HER2-amplified gastric cancer and particularly useful in combination therapies with HER2 inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsErb-b2 Receptor Tyrosine KinasesHistone Deacetylase InhibitorsPyridinesBenzamidesHumansAnimalsMiceCell Line, TumorXenograft Model Antitumor AssaysDown-RegulationGene Expression Regulation, NeoplasticCell ProliferationMicroRNAsApoptosisAntineoplastic Combined Chemotherapy ProtocolsFemale

Stichwörter der Autor:innen

EntinostatHDAC inhibitionHER2HER2 inhibitorsHistone deacetylasesStomach neoplasmsmiR-205

Substanzen

Erb-b2 Receptor Tyrosine KinasesHistone Deacetylase InhibitorsPyridinesBenzamidesMicroRNAsentinostatERBB2 protein, human

Autor:innen und Institutionen

  • Leipzig University, Medical Faculty, Rudolf-Boehm-Institute for Pharmacology and Toxicology, Clinical Pharmacology, Leipzig, Germany.
  • University Cancer Center Leipzig (UCCL), University Hospital Leipzig, Leipzig, Germany.
  • Comprehensive Cancer Center Central Germany (CCCG), Leipzig and Jena, Germany.
  • Department of Visceral, Transplant, Thoracic and Vascular Surgery, University Hospital of Leipzig, Leipzig, Germany.
  • University of Bonn, Pharmaceutical Institute, Department of Pharmaceutical and Cell Biological Chemistry, Bonn, Germany.

Förderung

  • Roland-Ernst-Stiftung für Gesundheitsforschung
  • German Research Foundation

Zitieren

APA

Zenz, T., Jenke, R., Thieme, R., Kahl, T., Borchardt, H., Gockel, I., Hansen, F. K., Aigner, A., & Büch, T. R. H. (2025). The Histone Deacetylase Inhibitor Entinostat Mediates HER2 Downregulation in Gastric Cancer, Providing the Basis for Its Particular Efficacy in HER2-Amplified Tumors and in Combination Therapies. Cancer Research and Treatment. https://doi.org/10.4143/crt.2024.546

Vancouver

Zenz T, Jenke R, Thieme R, Kahl T, Borchardt H, Gockel I, et al. The Histone Deacetylase Inhibitor Entinostat Mediates HER2 Downregulation in Gastric Cancer, Providing the Basis for Its Particular Efficacy in HER2-Amplified Tumors and in Combination Therapies. Cancer Research and Treatment. 2025. doi:10.4143/crt.2024.546

BibTeX
@article{Zenz2025,
  author = {Zenz, Tamara and Jenke, Robert and Thieme, René and Kahl, Tim and Borchardt, Hannes and Gockel, Ines and Hansen, Finn K and Aigner, Achim and Büch, Thomas R H},
  title = {The Histone Deacetylase Inhibitor Entinostat Mediates HER2 Downregulation in Gastric Cancer, Providing the Basis for Its Particular Efficacy in HER2-Amplified Tumors and in Combination Therapies},
  journal = {Cancer Research and Treatment},
  year = {2025},
  doi = {10.4143/crt.2024.546}
}
Kostenlos starten →